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CORRESPONDENCE OPEN
Little agreement in GOLD category using CAT and mMRC
in 450 primary care COPD patients in New Zealand
npj Primary Care Respiratory Medicine (2014) 24, 14025;
doi:10.1038/npjpcrm.2014.25; published online 24 July 2014
The updated 2011 Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines introduced a new method to categorise
chronic obstructive pulmonary disease (COPD) patients according
to risk and symptom level, whereas previously categorisation was
based solely on lung function impairment.1 Risk is classiﬁed as
either ‘low’ and ‘high’ based on lung function impairment (FEV1)
and exacerbation history. Symptom level can be assessed by using
the modiﬁed Medical Research Council (mMRC) dyspnoea scale,
the COPD Assessment Test (CAT) or the Clinical COPD Ques-
tionnaire (CCQ), the latter being added in the 2013 update.2
The guidelines state the recommended ﬁrst choice pharmaco-
logic therapy, an alternative choice and other possible treatments
for each category: A—‘low risk, less symptoms’; B—‘low risk, more
symptoms’; C—‘high risk, low symptoms’; or D—‘high risk, more
symptoms’.
It has been suggested that this new method of COPD patient
classiﬁcation should not be used in primary care because it could
lead to inappropriate management recommendations and the
categorisation process itself is too complex.3 As there are different
methods to assess symptoms, with all three having different
constructs and measurement properties,4 patients can fall into
different categories according to the method used.5 As a result,
clinicians can get different treatment recommendations depend-
ing on which method they use to assess symptoms.
We performed an audit of COPD patients in primary care to
assess whether there were signiﬁcant differences in GOLD
category depending on whether the mMRC or the CAT were
used, and also to determine the appropriateness of the medica-
tions that these patients were prescribed, according to GOLD
recommendations.
Four hundred and ﬁfty patients were assessed in three primary
care practices in New Zealand, and data were collected on patient
demographics, FEV1, exacerbation history, CAT and mMRC scores,
and prescribed medication.
The prescribed medication level was rated as ‘undertreated’,
‘well treated’, ‘over treated’ or ‘other regime’. To establish each
patient’s treatment level, their current medication use was
compared with each GOLD treatment recommendation (ﬁrst and
second choice for GOLD stage A, B, C and D, thus resulting in eight
‘yes’ or ‘no’ according to, e.g., ‘second choice treatment for stage
B’). ‘Well treated’ patients received pharmacotherapy that is listed
for GOLD’s recommendation for ﬁrst or second choice therapy for
their category. Patients who were prescribed medication that
corresponded to a lower or higher COPD category were rated
‘undertreated’ or ‘over treated’, respectively. Those who did not
receive any medication were rated as ‘undertreated’ and those
who were prescribed a combination of medications that did not
correspond to any of the GOLD recommendations were rated as
‘other regime’. Cohen’s kappa, a statistical method designed to
assess agreement over and above that due to chance between
two raters who each classify cases into categories, was used to
assess agreement of classiﬁcations of GOLD category and
treatment levels. A kappa of 1 represents perfect agreement,
whereas 0 indicates no agreement.
The mean age was 69 years (s.d. ± 10.1 years), 53% were males,
83% were New Zealand Europeans and 13% were Maori. The
mean FEV1 was 56 (±18.5)% of predicted value.
A graphical summary of the ﬁndings is shown in Figure 1.
Classifying patients using mMRC resulted in 30, 16, 16 and 38%
in groups A, B, C and D, and using CAT resulted in 17, 29, 8 and
46%, respectively. The agreement between the categorisation
using mMRC or CAT according to Cohen’s kappa was 0.62.
More than 50% of patients included in this audit were
prescribed medications that were not consistent with any ﬁrst or
second choice pharmacologic therapy listed in the GOLD guide-
line. A key ﬁnding was that 20% of patients were undertreated. In
particular, when using the CAT, a large proportion in group B were
undertreated, implying that a substantial proportion of patients
with high levels of symptoms were not prescribed long-acting
bronchodilators. In contrast, 68% of CAT-classiﬁed GOLD C
patients received inhaled corticosteroids, which is not recom-
mended for GOLD C patients. On average, patients in GOLD D
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Figure 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) category by treatment level by (a) modiﬁed Medical Research Council
Dyspnoea Scale and (b) COPD Assessment Test (CAT).
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used 2.7 (s.d. 1.2) different inhalers compared with 1.5 (s.d. 1.3)
in GOLD A.
The agreement in treatment level between patients categorised
using mMRC or CAT was 0.94.
The moderate agreement between using mMRC or CAT is
similar to that seen in two other studies that had values of 0.51
(ref. 5) and 0.63 (ref. 6). In those studies and this audit, using the
CAT led to a shift towards the ‘more symptoms’ categories, B and
D. The likely reason for this is that the mMRC assesses only
dyspnoea during exercise, whereas the CAT also assesses other
parameters such as cough, phlegm, chest tightness, breath-
lessness going up hills/stairs, activity limitation, sleep, energy and
conﬁdence leaving home. Therefore, the CAT is more likely to
reﬂect effects of COPD on a patient’s life than the mMRC. Also,
the CAT might be more sensitive to effects of co-morbidity than
the mMRC, e.g., orthopnea caused by heart failure might also
affect sleep.
In particular, use of the CAT resulted in the recategorisation of a
substantial number of patients from group A to B. This results in
more patients having long-acting bronchodilators recommended
for their treatment, and in this audit, it meant that the use of CAT
meant that more patients were classiﬁed as undertreated in group
B. The risk versus beneﬁt of earlier treatment with long-acting
bronchodilators is currently uncertain.
This audit and other similar studies are limited in that they have
only assessed cross-sectional differences in GOLD categorisation
and not changes in categorisation over time. The previous GOLD
classiﬁcation was solely based on FEV1 and as treatment did not
greatly affect FEV1, there was only limited movement between
categories and therefore treatment recommendations. However,
data from primary care suggest that many people change
categories over time,7,8 which could lead to step down of
treatments. More studies are required to assess the effects of
stepping down on outcomes. Although COPD is considered a
progressive disease, a reduction in treatment could positively
affect health by, e.g., reducing troublesome side effects. Also the
medication(s) may have been initiated for the ﬁrst, and perhaps,
only exacerbation the patient will experience and therefore may
not be required.
The decision as to which questionnaire to use in clinical practice
and how this would affect outcomes could not be answered based
on this study. To answer this question, a prospective longitudinal
study in which treatments are administered strictly according to
the categorisation based on the two (and now three) ques-
tionnaires recommended by GOLD and assessing important
clinical outcomes would be needed. However, based on feasibility
and applicability for primary care, the International Primary Care
Respiratory Group has previously recommended the use of the
CCQ or CAT.9
In summary, this audit found that there was a marked difference
in GOLD category depending on the method of symptom
assessment and that many patients are undertreated or prescribed
a treatment regime not consistent with the GOLD guideline.
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